Hepatic safety of ambrisentan alone and in combination with tadalafil: a post-hoc analysis of the AMBITION trial

Treatment with endothelin receptor antagonists (ERA) can result in adverse hepatic effects in patients with pulmonary arterial hypertension (PAH). We evaluated the hepatic safety of ambrisentan (ABS), an ERA, used as monotherapy, or with tadalafil (TAD), a phosphodiesterase-5 (PDE5) inhibitor as ini...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Krishna R., Blair, Christiana J., Tislow, James D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122251/
https://www.ncbi.nlm.nih.gov/pubmed/30124136
http://dx.doi.org/10.1177/2045894018797273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122251/
https://www.ncbi.nlm.nih.gov/pubmed/30124136
http://dx.doi.org/10.1177/2045894018797273

Ejemplares similares